Update on masitinib Phase 3 study in prostate cancer
31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer